158 related articles for article (PubMed ID: 38054983)
1. Statins in Graves Orbitopathy: A New Therapeutic Tool.
Lanzolla G; Comi S; Cosentino G; Pakdel F; Marinò M
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S29-S39. PubMed ID: 38054983
[TBL] [Abstract][Full Text] [Related]
2. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.
Lanzolla G; Vannucchi G; Ionni I; Campi I; Sileo F; Lazzaroni E; Marinò M
Front Endocrinol (Lausanne); 2019; 10():933. PubMed ID: 32038490
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis.
Li H; Yang L; Song Y; Zhao X; Sun C; Zhang L; Zhao H; Pan Y
Acta Ophthalmol; 2022 Sep; 100(6):e1189-e1198. PubMed ID: 34918472
[TBL] [Abstract][Full Text] [Related]
5. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
[TBL] [Abstract][Full Text] [Related]
6. Plasma Exosomes Transfer miR-885-3p Targeting the AKT/NFκB Signaling Pathway to Improve the Sensitivity of Intravenous Glucocorticoid Therapy Against Graves Ophthalmopathy.
Sun J; Wei J; Zhang Y; Li J; Li J; Yan J; Guo M; Han J; Qiao H
Front Immunol; 2022; 13():819680. PubMed ID: 35265076
[TBL] [Abstract][Full Text] [Related]
7. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
8. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
Nilsson A; Tsoumani K; Planck T
J Clin Endocrinol Metab; 2021 Apr; 106(5):1325-1332. PubMed ID: 33560351
[TBL] [Abstract][Full Text] [Related]
9. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant Therapy in Graves' Orbitopathy.
Lanzolla G; Marcocci C; Marinò M
Front Endocrinol (Lausanne); 2020; 11():608733. PubMed ID: 33381085
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
13. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
14. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
15. Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.
Naselli A; Moretti D; Regalbuto C; Arpi ML; Lo Giudice F; Frasca F; Belfiore A; Le Moli R
Front Endocrinol (Lausanne); 2020; 11():609895. PubMed ID: 33414766
[TBL] [Abstract][Full Text] [Related]
16. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
[TBL] [Abstract][Full Text] [Related]
17. Changes in ocular biomechanics after treatment for active Graves' orbitopathy.
Li HX; Zhao XH; Song Y; Mu BK; Pan Y; Zhao H; Wang Y
J Endocrinol Invest; 2021 Mar; 44(3):453-458. PubMed ID: 32507991
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
19. Statins: A New Hope on the Horizon of Graves Orbitopathy?
Marinò M; Lanzolla G; Marcocci C
J Clin Endocrinol Metab; 2021 Jun; 106(7):e2819-e2821. PubMed ID: 33735381
[No Abstract] [Full Text] [Related]
20. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
